查詢結果分析
相關文獻
- Hypothesis: Does "Autophagy Paradox" Strategy to Standard Therapy of Glioblastoma Multiforme Gain Benefit?
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- 攝護腺癌之傳統放射線治療--長庚紀念醫院十四年之經驗
- Preoperative Radiotherapy in Patients with Lower Rectal Cancer:Results of Sphincter-Preservation, Treatment Outcome and Morbidities
- A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx
- 成人低惡性度顱內星狀細胞瘤之術後放射治療
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
頁籤選單縮合
題 名 | Hypothesis: Does "Autophagy Paradox" Strategy to Standard Therapy of Glioblastoma Multiforme Gain Benefit?=假說:“自噬作用的悖論”,在多形性膠質母細胞瘤治療加上“自噬調控”藥物能增加治療效果嗎? |
---|---|
作 者 | 季懋欣; 楊凱琳; 柯卉玲; 季匡華; | 書刊名 | 放射治療與腫瘤學 |
卷 期 | 24:2 2017.06[民106.06] |
頁 次 | 頁119-127 |
分類號 | 415.938 |
關鍵詞 | 多形性膠質母細胞瘤; 放射治療; 自噬作用; Rapamycin; Hydroxychloroquine; Glioblastoma multiforme; Radiotherapy; Autophagy; |
語 文 | 英文(English) |
中文摘要 | 多形性膠質母細胞瘤(GBM)是最惡性的原發腦瘤。目前的標準治療為手術加上輔助性的放射及化學治療(temozolomide),然而此疾病預後仍是極差。有鑑於此,各式新型的藥物治療乃蓬勃發展。同時加上促進自噬作用的藥物:sirolimus(Rapamycin),與其抑制藥物hydroxychloroquine(HCQ, CQ)可以破壞癌症細胞從腫瘤微環境獲取能量的平衡。這個治療策略被稱為“自噬作用的悖論”。此方法已經在不同的癌症發現有逆轉藥物抗藥性的效果。細胞實驗發現GBM自噬作用不高,因而需要大量依賴腫瘤微環境供給能量成長。根據文獻探索與臨床經驗,我們假設在傳統化放療加上自噬作用調控的藥物對於多形性膠質母細胞瘤的治療是有助益的。 |
英文摘要 | Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Combined surgery, adjuvant radiotherapy (RT), and temozolomide (TMZ) is the standard treatment of care, but the outcome is still grave. Thus, novel therapeutic targets are actively researched in translational studies. Modulation of autophagy by simultaneous administration of the inducer, sirolimus (Rapamycin), and the inhibitor, hydroxychloroquine (HCQ), breaks the vicious cycle of energy supply from the tumor microenvironment (TME) to cancer cells. This strategy was called the "autophagy paradox". It has been applied to a variety of cancers to reverse drug resistance. A line of evidences including GBM are characterized by low autophagy capacity and highly dependent on the help of TME to provide energy source and biochemical building blocks for tumor growth and survival. Based on literature review and our experience, we hypothesize that add-on "autophagy paradox" strategy to standard RT-TMZ will be advantageous to GBM treatment. |
本系統中英文摘要資訊取自各篇刊載內容。